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Abstract 
Gallbladder mucocele (GBM) is a common extra-hepatic biliary syndrome in dogs with death rates 
ranging from 7-45%. Therefore, the aim of this study was to identify the association of survival 
with variables that could be utilized to improve clinical decisions. A total of 1194 dogs with a 
gross and histopathological diagnosis of GBM were included from 41 veterinary referral hospitals 
in this retrospective study.  
 
Dogs with GBM that demonstrated abnormal clinical signs had significantly greater odds 
of death than subclinical dogs in a univariable analysis (OR, 4.2; 95% CI, 2.14-8.23; P<0.001). 
The multivariable model indicated that categorical variables including owner recognition of 
jaundice (OR, 2.12; 95% CI, 1.19-3.77; P=0.011), concurrent hyperadrenocorticism (OR 1.94; 
95% CI, 1.08-3.47; P=0.026), and Pomeranian breed (OR, 2.46; 95% CI 1.10-5.50; P=0.029) were 
associated with increased odds of death, and vomiting was associated with decreased odds of death 
(OR, 0.48; 95% CI, 0.30-0.72; P=0.001). Continuous variables in the multivariable model, total 
serum/plasma bilirubin concentration (OR, 1.03; 95% CI, 1.01-1.04; P<0.001) and age (OR, 1.17; 
95% CI, 1.08-1.26; P<0.001), were associated with increased odds of death. The clinical utility of 
total serum/plasma bilirubin concentration as a biomarker to predict death was poor with a 
sensitivity of 0.61 (95% CI, 0.54-0.69) and a specificity of 0.63 (95% CI, 0.59-0.66). This study 
identified several prognostic variables in dogs with GBM including total serum/plasma bilirubin 
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concentration, age, clinical signs, concurrent hyperadrenocorticism, and the Pomeranian breed. 
The presence of hypothyroidism or diabetes mellitus did not impact outcome in this study.  
 
Keywords: Canine Cushing’s; Cholecystectomy; Gallbladder mucocoele; Hypothyroidism; 
Survival 
 
Introduction 
Gallbladder mucocele (GBM) in dogs is defined as a distended gallbladder with an 
abnormal accumulation of thick amorphous mucin in conjunction with histologic evidence of 
mucosal hypertrophy, formation of mucus-filled cysts, and long, thin branching fronds of well 
differentiated gallbladder epithelial cells (Gookin et al., 2015; Kesimer et al., 2015; Pike et al., 
2004; Stalker et al., 2007). The syndrome has emerged as one of the most commonly identified 
causes of biliary disease in dogs over the last 10 years (Gookin et al., 2015). The clinical 
importance of GBM relates to the morbidity and mortality associated with extrahepatic biliary duct 
obstruction, gallbladder rupture, biliary infection, and systemic inflammatory response syndrome 
that can occur secondary to gallbladder wall necrosis, infarction, or perforation (Jaffey et al., 
2018).  
 
The optimal time for surgical intervention in dogs with GBM that demonstrate clinical 
signs associated with biliary tract disease has not been defined. Over the last 20 years there has 
been a shift towards early surgical intervention in people with acute cholecystitis (Lo et al., 1998). 
Performing cholecystectomy in people with acute cholecystitis within 72 hours of time of onset of 
symptoms significantly decreases the overall incidence of complications, including perioperative 
blood loss, length of hospital stay, wound infection, overall morbidity, and mortality (Cao et al., 
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2016; Gonzalez-Rodriguez et al., 2009; Lau et al., 2006). While not directly comparable to canine 
GBM, some of these concerns regarding cholecystitis in people are likely to be of relevance, 
particularly as cholecystitis and regional inflammation has been observed in some dogs with GBM 
(Malek et al., 2013; Pike et al., 2004; Tamborini et al., 2016; Wennogle et al., 2019; Rogers et al., 
in press). 
 
The average time from the onset of clinical signs to surgery in dogs with GBM according 
to one small study is approximately 8 days (Worley et al., 2004). However, the relationship 
between timing of cholecystectomy and outcome has not been investigated in dogs with GBM. 
Furthermore, there is limited information related to the impact of abnormal clinical signs 
associated with biliary tract disease in dogs with GBM on survival. In a recent retrospective study, 
dogs that demonstrated one or more clinical sign attributable to biliary tract disease had a 
significantly greater mortality rate than dogs that were subclinical at the time of cholecystectomy 
(Youn et al., 2018). However, this study did not investigate the effect of specific clinical signs and 
survival in a multivariable model. 
 
Hyperbilirubinemia is reported to occur in approximately 52% to 100% of dogs with GBM 
(Crews et al., 2009; Malek et al., 2013; Youn et al., 2018). Hyperbilirubinemia is a preoperative 
risk factor for death in dogs undergoing biliary surgery and total serum/plasma bilirubin 
concentrations predict a shorter survival time in Shetland sheepdogs with gallbladder disease and 
in dogs with acute and chronic hepatopathies (Aguirre et al., 2007; Amsellem et al., 2006; 
Dereszynski et al., 2008; Ferguson et al., 2011; Gomez Selgas et al., 2014; Kilpatrick et al., 2016; 
Lester et al., 2016; Poldervaart et al., 2009). There is limited information regarding the utility of 
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total bilirubin concentration as a biomarker for survival in dogs with GBM despite 
hyperbilirubinemia being a common clinicipathologic abnormality in dogs with GBM and its 
association with decreased survival in dogs with biliary surgery. 
 
Chronic hypercortisolemia (Worley et al., 2004), hypothyroidism (Ekmektzoglou and 
Zografos, 2006; Ladenson et al., 1984; Safer, 2013; Safer et al., 2004), and diabetes mellitus (DM; 
Ekmektzoglou and Zografos, 2006; Hickman et al., 1988) have been shown to negatively impact 
wound healing and substantially increase the risk of surgery-related morbidity and death in a 
variety of species. Dogs with hyperadrenocorticism (i.e. hypercortisolemia; Gookin et al., 2015; 
Mesich et al., 2009), hypothyroidism (Mesich et al., 2009), and hyperlipidemia (Kutsunai et al., 
2014) have significantly higher odds of having a GBM. However, the possibility of an association 
between hyperadrenocorticism, hypothyroidism, and hyperlipidemia and outcome in dogs with 
GBM has not been evaluated. Understanding this relationship is clinically important because of 
how common GBM occur in dogs with hyperadrenocorticism, hypothyroidism, DM, and 
hyperlipidemia. 
 
The present study had four objectives. The first was to determine if timing of 
cholecystectomy after recognition of clinical signs impacted survival. Our second objective was 
to investigate if there was a difference in outcome between dogs with or without clinical signs 
attributable to GBM. The third objective was to determine if a diagnosis of concurrent 
hyperadrenocorticism, hypothyroidism, DM, or hyperlipidemia was associated with increased 
death. The final objective of our study was to evaluate total serum/plasma bilirubin concentration 
as a prognostic biomarker. We hypothesized that greater time (days) from initial recognition of 
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clinical signs to cholecystectomy in dogs with GBM would be significantly associated with death. 
Further, we hypothesized that dogs with clinical signs attributable to GBM at the time of 
cholecystectomy would be more likely to die than dogs without clinical signs. Next, we 
hypothesized that dogs with comorbidities (hyperadrenocorticism, hypothyroidism, DM, and 
hyperlipidemia) would be more likely to die than dogs without these comorbidities. Lastly, we 
hypothesized that total serum/plasma bilirubin concentration could be used to predict death.  
 
Materials and Methods 
Criteria for Selection of Cases 
A retrospective, multi-center, case series was performed. Multiple institutions throughout 
the United States of America, Canada, Australia, Asia, South America and Europe were contacted 
for participation in this study. This was achieved by direct communication via email with board-
certified small animal internists with contact information available in the American College of 
Veterinary Internal Medicine and European College of Veterinary Internal Medicine – Companion 
Animal directory. Only institutions with at least one boarded small animal specialist (i.e. internal 
medicine, surgeon, clinical pathologist, or criticalist) were eligible for participation. Medical 
records of dogs that had gross and histopathologic diagnosis of GBM after cholecystectomy 
examined between January 2007 and January 2017 were requested. Cases were identified at each 
institution by searching medical records, histopathology and surgery logs for ‘gallbladder 
mucocele/mucocoele’, ‘mucocele/mucocoele’, and ‘cholecystectomy’. Some data from this cohort 
was previously reported in studies with different objectives (Allerton et al., 2018; Jaffey et al., 
2018; Rogers et al., in press). This study was approved by the Clinical Research Ethical Review 
Board of the University of Edinburgh (# 132.17; date of approval 11 th November 2017) and 
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University of Nottingham (# 2149.171108; date of approval 7th November 2017). The remaining 
institutions obtained dog owner signed consent on standard hospital admission documents that 
outline permission for use of data from medical records for research. All histologic interpretations 
were made by board-certified veterinary pathologists or the equivalently trained expert as dictated 
by the scientific standards of the geographic region. Likewise, all cholecystectomies were 
performed by, or under the direct supervision of, a boarded-veterinary surgeon or the equivalently 
trained expert as dictated by the scientific standards of the geographic region. 
 
The data retrieved from medical records included: beginning and ending dates of medical 
records undergoing review; age; breed; sex; histologic features consistent with GBM; time (days) 
from the onset of clinical signs to surgery; description of clinical signs; the presence of 
hyperadrenocorticism, hypothyroidism, DM, or combination thereof; treatment for 
hyperadrenocorticism, hypothyroidism, and DM; blood biochemical data (total bilirubin, 
triglyceride, and cholesterol concentrations); survival to discharge; and cause of death. All 
biochemical data were obtained during the hospitalization associated with cholecystectomy or 
death. 
 
A diagnosis of GBM was made based on gross appearance of a distended gallbladder with 
an abnormal accumulation of thick amorphous mucin in conjunction with histologic evidence of 
mucosal hypertrophy, formation of mucus-filled cysts, and long, thin branching fronds of well 
differentiated gallbladder epithelial cells (Gookin et al., 2015; Kesimer et al., 2015; Pike et al., 
2004; Stalker et al., 2007). A dog was considered to have hypothyroidism or hyperadrenocorticism 
if a historical diagnosis was present at the time of cholecystectomy. A dog was considered to have 
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hypothyroidism if serum (total or free) T4 concentration was less than the lower limit of the 
reference interval and concurrent serum TSH concentration was greater than the upper limit of the 
reference interval of the respective laboratory (Mesich et al., 2009). A dog was considered to have 
hyperadrenocorticism if a low-dose dexamethasone suppression test or ACTH stimulation test 
results were positive according to the laboratory-derived cutoffs used for hyperadrenocorticism 
and consistent clinical signs were present (e.g. polyuria, polydipsia, polyphagia, panting, 
abdominal distension; Mesich et al., 2009). A dog was considered to have DM if a historical 
diagnosis was present or if hyperglycemia, glucosuria, and clinical signs consistent with DM were 
identified at the time of evaluation (Mesich et al., 2009). Hyperlipidemia was defined as an increase 
in the blood concentration of cholesterol, triglycerides, or both (De Marco et al., 2017; Lee et al., 
2017). Both cholesterol and triglyceride concentrations were required to be less than the upper 
limit of each reference interval to rule out hyperlipidemia in order to minimize potential false 
negatives related to missing data for either parameter. Dogs were considered to have clinical signs 
attributable to biliary tract disease if the owner reported vomiting, lethargy, anorexia, hyporexia, 
pain, jaundice, diarrhea, hypodipsia, adipsia, weakness, fever, and abdominal distension in the 7 
days prior to presentation. Death-in-hospital was the primary outcome of interest, and was defined 
collectively, as in-hospital death or euthanasia in dogs with GBM that had undergone a 
cholecystectomy. Survival after hospital discharge was not assessed in this study. 
 
Statistical Analysis  
Statistical analysis was performed using commercially available software (STATA SE, 
v.15.1, StataCorp, College Station, TX). The Shapiro-Wilk test was used to assess normality of 
continuous numerical variables. The data with non-normal distribution were presented as median, 
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Q1, Q3, and range. Analyses of total serum/plasma bilirubin concentration were made based on 
the fold change with respect to the upper limit of the corresponding reference interval (i.e. total 
serum/plasma bilirubin concentration / upper limit of the reference interval). A receiver-operating 
characteristic (ROC) curve was used to determine the area under the curve (AUC) and select the 
optimum cut-off value of the fold change in total serum/plasma bilirubin concentration for 
prediction of death-in-hospital that maximized the Youden’s J statistic for sensitivity and 
specificity reporting.  
 
Patient data were considered clustered within hospital; and all regression models were 
fitted as random-effects logit models with death as the binary outcome of interest. Coefficients in 
the models were exponentiated to produce odds ratios. Numerical variables, age and duration of 
clinical signs before surgery, were assessed in regression as continuous variables and also 
categorized into quartiles and quintiles, respectively, based on natural breaks in the data. Model 
comparison was based on Akaike information criteria (AIC) and Bayesian information criteria 
(BIC), and for both variables analysis as continuous variables was chosen as equivalent or superior 
to division into quartiles/quintiles. 
 
Univariate random-effects logistic regression analyses were performed to screen for the 
association between death and the independent variables of interest. Comorbidities as 
hyperadrenocorticism, hypothyroidism, DM, hyperlipidemia, hypercholesterolemia, 
hypertriglyceridemia were included in regression analyses as dichotomous variables with absence 
of the comorbidity as the referent. Covariates screened individually using univariable logistic 
regression and having a liberal P-value cutoff, i.e. P<0.20, were included in the final multivariable 
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analysis. The level of significance was set at P<0.05 for the multivariable analysis, as well as all 
other statistical tests, and only variables with P-values <0.05 were retained in the final reported 
model. Confounding was assessed by determining if individual variable odds ratios changed by 
>20% with inclusion/removal of additional variables. 
 
Results 
Animal population 
A total of 1194 dogs from 38 academic veterinary hospitals and 3 private practice specialty 
hospitals in 20 countries were included in the study. Collaborators were recruited through direct 
contact with referral centers. Medical record system changes altered the study period from four 
institutions (Supplemental Table S1). No dogs were excluded.  
 
There was a total of 1006 purebred dogs and 188 mixed breed dogs (Supplemental Table 
S2). The most commonly represented breeds (i.e. those comprising >30 dogs) were Mixed breed 
dogs, Shetland sheepdog, Cocker spaniel, Miniature schnauzer, Bichon frise, Beagle, Pomeranian, 
Border terrier, Chihuahua, and Shih tzu (Supplemental Table S1). The median age was 10 years 
(Q1, Q3, range; 8.0, 12.0, 2.0-17.0 years). There were 546 spayed females, 496 castrated males, 
86 intact males and 66 intact females. 
 
All 1194 dogs had a cholecystectomy performed. Medical records detailing the presence 
or absence of clinical signs attributable to biliary tract disease (i.e. clinical or subclinical) at the 
time of cholecystectomy were available for 99.9% (1193/1194) dogs (Fig.1). A total of 17.6% 
(211/1194) of dogs did not exhibit clinical signs at the time of cholecystectomy. The reason for 
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cholecystectomy was available for 84.8% (179/211) of dogs that were subclinical. The indication 
for surgery in these 179 dogs included prophylactic surgery after an incidental ultrasonographic 
identification of GBM in 62.6% (112/179), failure of improvement in liver enzyme activities or 
lack of ultrasonographic resolution of GBM after medical management in 12.8% (23) of dogs, and 
concomitant increase in liver enzyme activities and ultrasonographic identification of GBM in 
6.7% (12). A total of 17.9% (32/179) of dogs had a planned cholecystectomy in conjunction with 
another surgery or it was performed at the discretion of a surgeon during an unrelated procedure 
(Supplemental Table S3).  
 
Eighty-two percent (982/1194) of dogs with GBM demonstrated at least one clinical sign 
attributable to biliary tract disease, and those most commonly reported (i.e. in more than >10% of 
dogs) included vomiting 80.0% (786/982), lethargy 46.7% (458/982), anorexia 46.2% (454/982), 
diarrhea 18.3% (180/982), painful abdomen 16.7% (164/982), hyporexia 11.2% (110/982), and 
jaundice 9.8% (96/982). The remaining distribution of clinical signs are provided in Supplemental 
Table S4. Information on the duration of clinical signs prior to cholecystectomy was available in 
98.4% (966/982) of dogs; the median time was 4 days (Q1, Q3, range; 2.0, 7.0, 1.0–730 days).  
 
A total of 84.4% (1008/1194), 19.4% (232/1194), and 19.0% (227/1194) dogs had 
cholesterol and triglyceride concentrations, or both measured, respectively. Hyperlipidemia was 
identified in 90.8% (585/644) dogs. Hypercholesterolemia was found in 55.4% (559/1008) and 
hypertriglyceridemia was identified in 48.3% (112/232) of dogs. Twenty-six percent (59/227) of 
dogs had normocholesterolemia and normotriglyceridemia. Total serum/plasma bilirubin 
Jo
ur
na
l P
re
-p
ro
of
13 
 
concentration was measured in 92.4% (1103/1194) of dogs, of which the median was 2.3 times the 
upper limit of the reference interval (Q1, Q3, range; 0.67, 11.2, 0.0-135).  
 
Of the 10.1% (120/1194) of dogs diagnosed with hyperadrenocorticism, 61.7% (74/120) 
were undergoing medical management at the time of cholecystectomy. Of the 6.1% (73/1194) of 
dogs diagnosed with hypothyroidism, all (73/73) were undergoing medical management at the 
time of cholecystectomy. Of the 5.8% (69/1194) of dogs diagnosed with DM, all (69/69) were 
undergoing medical management at the time of cholecystectomy.  
 
Death-in-hospital occurred in 15.0% (179/1194; 95% CI 13.0-17.1%) of dogs that 
underwent cholecystectomy for GBM. Ninety-six of these dogs were euthanased and 83 died. 
Death-in-hospital occurred in 17.1% (168/982) of dogs that demonstrated clinical signs 
attributable to biliary tract disease at the time of cholecystectomy, compared to 4.7% (10/211) of 
dogs that were subclinical. The one dog without a clinical status prior to surgery available, died 
following cholecystectomy. Of the dogs that were subclinical and had cholecystectomy performed 
for prophylactic purposes in absence of a concurrent procedure 5.4% (6/112) had death-in-hospital. 
The reason for euthanasia and cause for death was reported for all (96/96) and 45.8% (45/83) of 
dogs, respectively (Supplementary Table S5).  
 
Total serum/plasma bilirubin concentration as a biomarker to predict to death-in-hospital  
The area under the ROC curve for total serum/plasma bilirubin concentrations in relation 
to survival-to-discharge in dogs with GBM was 0.64 (95% CI, 0.60-0.69). The optimal cutoff was 
4.3 times the upper limit of the reference interval, with a greater increase being consistent with 
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death-in-hospital. Using this cutoff, a sensitivity of 0.61 (95% CI, 0.54-0.69) and a specificity of 
0.63 (95% CI, 0.59-0.66) for the prediction of death-in-hospital was achieved (Table 1).  
 
Univariable analysis 
Variables pertaining to patient signalment that were significant in univariate screening 
(P<0.20; Table 2; Fig.1) for increased odds of death-in-hospital included being neutered/spayed 
(OR, 1.69; 95% CI, 0.95-3.01; P=0.072) and increasing age (OR, 1.14; 95% CI, 1.07-1.22; 
P<0.001). Breeds with significant associations included reduced odds of death for Miniature 
schnauzers (OR, 0.27; 95% CI, 0.08-0.88; P=0.030) and increased odds of death for Pomeranians 
(OR, 1.67; 95% CI, 0.82-3.42; P=0.159; Table 3).  
 
Dogs with GBM that demonstrated clinical signs attributable to biliary tract disease had 
significantly greater odds of death than subclinical dogs in a univariable analysis (OR, 4.20; 95% 
CI, 2.14-8.23; P<0.001; Table 4). Owner recognition of jaundice was associated with increased 
odds of death-in-hospital (OR, 2.33; 95% CI, 1.40-3.89; P=0.01), whereas vomiting was 
associated with decreased odds of death (OR, 0.52; 95% CI, 0.34-0.78; P=0.001; Table 4). Total 
serum/plasma bilirubin concentration (OR, 1.03; 95% CI, 1.02-1.04; P<0.001) and 
hyperadrenocorticism (OR, 1.68; 95% CI, 1.04-2.70; P=0.035; Table 5) were associated with 
increased odds of death-in-hospital, but hyperlipidemia, hypercholesterolemia, duration of clinical 
signs, and presence of other endocrinopathies were not associated with odds of death (Table 5; 
Fig.1) 
 
Multivariable analysis 
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 Variables selected from screening that remained statistically significant (P<0.05) in the 
final multivariable regression model included age (OR 1.17; P<0.001), Pomeranian breed (OR 
2.46; P = 0.029), presence of owner-identified jaundice (OR 2.12; P=0.011), quantitative increase 
in total serum/plasma bilirubin concentration (OR 1.03; P<0.001), and concurrent 
hyperadrenocorticism (OR 1.94; P=0.026) all increasing the odds of death, and presence of 
vomiting decreasing the odds of death (OR 0.48; P=0.001; Table 1; Fig.1).  
 
Discussion 
This international, multi-center study included over 1000 dogs, making it the largest GBM 
study to date. This study investigated important variables with clinical plausibility to impact 
survival-to-discharge including time from initial recognition of clinical signs to cholecystectomy, 
presence or absence of clinical signs attributable to biliary tract disease, presence of 
hyperlipidemia, total serum/plasma bilirubin concentration, age, sex, breed, and presence of 
endocrinopathy (i.e. DM, hyperadrenocorticism, hypothyroidism). The results from this study 
indicate that the continuous variables total serum/plasma bilirubin concentration and age, as well 
as the categorical variables concurrent hyperadrenocorticism, Pomeranian breed, and owner 
recognition of jaundice at the time of initial evaluation, were associated with increased odds of 
death. Unexpectedly, owner recognition of vomiting at the time of evaluation conferred a 
protective effect in our population. Lastly, while increasing total serum/plasma bilirubin 
concentration was associated with increased odds of death in this study, it proved to be a poor 
biomarker to predict death.  
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Hyperbilirubinemia is a preoperative risk factor for death in dogs undergoing biliary 
surgery and total serum/plasma  bilirubin concentrations predict a shorter survival time in Shetland 
sheepdogs with gallbladder disease and in dogs with acute and chronic hepatopathies (Aguirre et 
al., 2007; Amsellem et al., 2006; Dereszynski et al., 2008; Ferguson et al., 2011; Gomez Selgas et 
al., 2014; Kilpatrick et al., 2016; Lester et al., 2016; Poldervaart et al., 2009). Likewise, total 
serum/plasma bilirubin concentration in the present study conferred a significant increase in odds 
of death-in-hospital. Hyperbilirubinemia in dogs with GBM likely reflects more severe or 
progressive disease with the presence of complications such as gallbladder rupture, pancreatitis, 
partial or complete extrahepatic bile duct obstruction, significant functional hepatobiliary disease, 
or endotoxin-induced (cholestasis of sepsis), which have the potential to compromise survival after 
cholecystectomy (Buote et al., 2006; Jaffey et al., 2018; Mayhew et al., 2002; Wang and Yu, 2014). 
The aforementioned variables were not evaluated in this study but warrant future investigations to 
better understand the pathogenesis and impact hyperbilirubinemia has on survival in dogs with 
GBM. While increasing total serum/plasma bilirubin concentrations proved to be significantly 
associated with death in this study, its utility as a clinically reliable biomarker to predict death was 
unacceptably poor. In other words, increasing total serum/plasma bilirubin concentrations in dogs 
with GBM can be interpreted as a negative prognostic indicator but cannot be relied upon to predict 
outcome. 
 
Dogs with GBM that demonstrated clinical signs attributable to biliary tract disease at the 
time of cholecystectomy had 4.2 times the odds of death than dogs that were subclinical in a 
univariable logistic regression analysis. When evaluated in a multivariable model, the presence of 
clinical signs (present/absent) lost significance when adjusted for specific clinical signs. The final 
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multivariable model indicated that owner recognition of jaundice was associated with 2.1 times 
the odds of death. The sclera and skin have detectable icterus when serum bilirubin is >51.3 to 
68.4 mol/L [>3 to 4 mg/dl] in dogs (Williard et al., 2012). Therefore, the magnitude of 
hyperbilirubinemia was likely severe if untrained dog owners were capable of recognizing it and 
as identified in our study, increasing total serum/plasma bilirubin concentration was associated 
with increased odds of death. Unexpectedly, dog owner recognition of vomiting was associated 
with 0.46 times the odds of death than when vomiting was not reported. It is possible that dogs 
evaluated for GBM without vomiting had more advanced disease. This interesting finding warrants 
additional investigation. The clinical progression of dogs with incidentally discovered GBM is 
poorly understood as is the impact of elective cholecystectomy on survival in these dogs (Clemente 
et al., 2017; Kesimer et al., 2015). Moreover, the long-term benefit of conservative medical therapy 
in dogs with GBM is scarce. One retrospective study found that none of the 15 dogs with 
hyperadrenocorticism treated with trilostane for 6 months had resolution of GBM (Kim et al., 
2017). However, there is a report that describes GBM resolution in two dogs following medical 
management (Walter et al., 2008). Therefore, the finding that once clinical signs develop survival 
decreases suggests prospective studies evaluating the impact of early surgical intervention for 
incidentally discovered GBM on survival are warranted. 
 
Dog breeds that have been reported to be over-represented for GBM include Shetland 
sheepdog, Cocker spaniel, Miniature schnauzers, and Border terriers (Aguirre et al., 2007; Allerton 
et al., 2018; Jaffey et al., 2018). Further, one study reported that Shetland sheepdogs with GBM 
formation were 9.3 times more likely to have been treated with imidacloprid than Shetland 
sheepdogs without GBM (Gookin et al., 2015). However, to the authors’ knowledge, previous 
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studies have not identified breed associations with survival in dogs with GBM. Pomeranian breed 
dogs had 2.3 times the odds of death than other breeds with GBM in the present study. A specific 
pattern for cause of death in the Pomeranians in our study could not be established because the 
majority experienced cardiopulmonary arrest of unknown etiology. However, of the Pomeranian 
dogs that were euthanased or died, the most common reasons were hypoxemia and refractory 
hypotension. Pomeranians are one of the most common breeds affected by tracheomalacia, which 
could have contributed to post-operative hypoxemia and refractory hypotension (Buback et al., 
1996; Macready et al., 2007). Future studies are needed to investigate the cause for increased odds 
of death in Pomeranian dogs with GBM.  
 
Advancing age was associated with increased odds of death-in-hospital in our study, 
consistent with many different studies investigating risk factors for diseases in dogs (Hanson et 
al., 2007; Mattin et al., 2018). Survival studies in veterinary literature are subject to the 
confounding variables that influence euthanasia. It is possible dogs with advanced age in this study 
were more likely to develop a severe complication related to accrued comorbidities that were not 
evaluated in our study. However, it is also possible that clinicians and dog owners perceived 
advanced age negatively and opted towards euthanasia if complications arose. Therefore, the 
authors caution against utilization of advanced age as a stand-alone negative prognostic indicator 
in dogs with GBM. 
 
A concurrent diagnosis of hyperadrenocorticism at the time of cholecystectomy in dogs 
with GBM yielded an approximately 2-fold increase in odds of death-in-hospital than dogs without 
a diagnosis of hyperadrenocorticism. There are several possible explanations for this finding. We 
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did not determine the severity of illness, duration of illness, remission status or evaluate for 
evidence of iatrogenic hypoadrenocorticism in dogs with hyperadrenocorticism in this study. 
Additionally, dogs were categorized as having hyperadrenocorticism only if identified before the 
time of cholecystectomy. It is possible that the dogs with a pre-operative diagnosis of 
hyperadrenocorticism had more severe hypercortisolemia and more advanced or severe disease for 
a longer period of time, which prompted their earlier diagnosis. Only 10% of dogs in this study 
had a pre-operative diagnosis of hyperadrenocorticism and the majority of those dogs were being 
medically managed at the time of cholecystectomy. This small subset of dogs made statistical 
evaluation of the impact of medical management of hyperadrenocorticism on outcome in dogs 
with GBM unreliable and was not pursued. Hypercortisolemia in dogs with hyperadrenocorticism 
without medical management or poor control of disease can result in several potential deleterious 
consequences including hypercoagulability (Park et al., 2013; Rose et al., 2013), decreased wound 
healing (Wang et al., 2013), and immune system dysregulation (Mori et al., 2009). Conversely, 
medically managed dogs could be susceptible to either relative or absolute iatrogenic 
hypoadrenocorticism at the time of cholecystectomy. Eucortisolemia or true hypocortisolemia 
could have produced a physiologic syndrome similar to critical illness related corticosteroid 
insufficiency (i.e. a state of relative adrenal insufficiency), which has been associated with 
decreased survival in critically ill dogs (Burkitt et al., 2007). Future prospective studies are 
required to investigate the role of medical management of hyperadrenocorticism in dogs with 
GBM prior to cholecystectomy 
 
Performing cholecystectomy in people with acute cholecystitis within 72 hours of the onset 
of symptoms significantly decreases overall morbidity and mortality (Cao et al., 2016; Gonzalez-
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Rodriguez et al., 2009; Gutt et al., 2013; Johansson et al., 2003; Johansson et al., 2005; Kolla et 
al., 2004; Lai et al., 1998; Lau et al., 2006; Saber and Hokkam, 2014). In contrast to people with 
acute cholecystitis, time (days) from the initial recognition of abnormal clinical signs to 
cholecystectomy was not associated with survival in dogs with GBM in this study when evaluated 
as a continuous or categorical variable. The problems associated with delayed surgical intervention 
(i.e. >72 hours) in people with acute cholecystitis are speculated to arise from prolonged regional 
inflammation and life-threatening complications including gallbladder perforation, bile peritonitis, 
pericholecystic abscess, and the development of a biliary fistula (Kimura et al., 2007). While acute 
cholecystitis in people is not directly comparable to dogs with GBM, it is reasonable to suspect 
the sequela of both diseases could be similar. The reliance on dog owners’ perception of when 
clinical signs started was subject to various uncontrolled variables related to the dog owner (e.g. 
medical background, perceptiveness, multiple owners with conflicting opinions, and accurate 
memory). However, in the absence of a canine GBM experimental model dependence on dog 
owners’ historical perception of their dog’s clinical signs while a limitation, is essential, and 
clinically applicable. As it is not possible to reliably determine whether cholecystitis is present 
alongside GBM then owners should be advised of a likely increased risk of adverse outcome were 
cholecystitis present and cholecystectomy not performed with urgency. The frequency of 
concurrent cholecystitis in dogs with GBM is reported to range from 9% to 68% (median, 25%; 
Pike et al., 2004; Malek et al., 2013; Wennogle et al., 2019; Rogers et al., In press). 
 
The main limitations of this study are associated with its retrospective nature. Outcome in 
the present study was defined as death-in-hospital, which might have underestimated the overall 
death rate attributed to dogs with GBM undergoing cholecystectomy. The inclusion criteria of 
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gross and histopathologically confirmed GBM were intentionally strict to optimally investigate the 
primary aims. This strict approach likely omitted dogs that did not have histopathology performed, 
or died or were euthanased intra- or post-operatively then had histopathologic evaluation 
withdrawn. Not every dog in this cohort was screened for an endocrinopathy or had the necessary 
biochemical parameters evaluated to diagnose hyperlipidemia. On that note, the decision to 
perform various types of diagnostics varied with clinician preference. The decision to evaluate 
cholesterol and/or triglycerides could have been biased towards grossly lipemic samples. 
Biochemical parameters were evaluated using different analyzers with various reference intervals. 
This was mitigated by evaluating cholesterol and triglyceride in relation to the upper limit of the 
laboratory reference interval and categorizing them as either hypercholesterolemia or 
hypertriglyceridemia. Moreover, total serum/plasma bilirubin concentration analyses were made 
based on the fold change with respect to the upper limit of each laboratory reference interval. 
Survival analyses in our study did not include previously identified prognostic variables in dogs 
with GBM including lymphocyte count (Crews et al., 2009), gallbladder rupture (Jaffey et al., 
2018), postoperative serum lactate concentrations, and postoperative hypotension, which was a 
limitation (Malek et al., 2013). The inclusion of euthanased dogs in our survival analyses was a 
limitation. It is possible some of these dogs were euthanased for reasons unrelated to severity of 
disease (e.g. owner finances, owner objection to treatment, or clinician recommendation). 
Inclusion of dogs that were euthanased in the death-in-hospital group precludes our ability to truly 
determine if dogs with certain risk variables are more likely to die naturally. For example, there 
might be an underlying perception by attending clinicians that clinical signs coupled with 
hyperbilirubinemia in this population is associated with a poorer outcome. Relaying this perception 
to owners might have increased the likelihood of euthanasia, when a portion of these dogs could 
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have survived. A prospective study that allows clinicians to provide a detailed description of the 
circumstances leading to euthanasia would be able to provide a better understanding of the link 
between some of these variables and survival. However, despite the inherent biases and data issues 
associated with a multi-center retrospective study, the large volume of cases, and diverse 
geographic source of care included make the conclusions robust. 
 
Conclusions 
The findings of the present study indicate that increased total serum/plasma bilirubin 
concentration is a negative prognostic indicator but is an unacceptably poor biomarker for 
predicting death-in-hospital in dogs with GBM at the time of cholecystectomy. The presence of 
clinical signs attributable to biliary tract disease at the time cholecystectomy yielded significantly 
greater odds of death-in-hospital than subclinical disease status in a univariable analysis. In the 
final multivariable model, owner recognition of jaundice was associated with increased odds of 
death-in-hospital. Pomeranian breed dogs were more likely to die in hospital following 
cholecystectomy than other breeds with GBM in our study. Concurrent hyperadrenocorticism was 
associated with nearly a 2-fold increase in odds for death in this study. The presence of 
comorbidities including hyperlipidemia, DM, hypothyroidism, and time (days) from initial 
recognition of clinical signs to cholecystectomy, were not associated with survival.  
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Figure legend 
Fig. 1. Flow diagram. A total of 1194 dogs with gallbladder mucoceles were included in the study. 
a There were no dogs excluded. Several potentially clinically significant variables were included 
in univariable logistic regression analyses. b The 10 most common breeds were included (i.e. 
Mixed breed, Shetland sheepdog, Cocker spaniel, Miniature schnauzer, Bichon frise, Pomeranian, 
Border terrier, and Chihuahua). c One dog did not have a clear distinction if clinical signs were 
present or absent in the 7-days preceding cholecystectomy. d The seven most commonly reported 
clinical signs (i.e. vomiting, hyporexia, anorexia, jaundice, painful abdomen, diarrhea, and 
lethargy). e Biochemical parameters (total serum/plasma bilirubin, cholesterol, and triglyceride 
concentrations) were performed at the discretion of the attending clinician, which resulted in 
missing data for these variables. f Time (days) from initial recognition of clinical signs to 
cholecystectomy was missing in 16/982 clinical dogs. Significant variables in the univariable 
analyses (P<0.20) were included in the initial multivariable model. The final multivariable model 
retained significant variables (P<0.05) with 915 total observations. 
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Table 1 Sensitivity and specificity of fold change, with respect to the upper reference interval, of 
total serum/plasma bilirubin concentration at time of presentation for prediction of death-in-
hospital for dogs following cholecystectomy for gallbladder mucocoele management using 
different cutoff values.  
 
Cutoff (fold increase) Sensitivity 95% CI Specificity 95% CI 
0.01 1.00 0.98-1.00 0.01 0.01-0.02 
1.32 0.77 0.70-0.83 0.42 0.39-0.46 
2.00 0.70 0.62-0.77 0.51 0.48-0.54 
3.00 0.66 0.58-0.73 0.58 0.55-0.61 
4.00 0.63 0.55-0.71 0.61 0.58-0.65 
4.30 0.61 0.54-0.69 0.63 0.59-0.66 
8.60 0.47 0.39-0.55 0.74 00.71-0.76 
10.10 0.42 0.34-0.49 0.76 0.73-0.79 
15.00 0.28 0.21-0.35 0.83 0.81-0.86 
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20.20 0.19 0.14-0.26 0.88 0.86-0.90 
71.67 0.01 0.00-0.04 1.00 0.98-1.00 
CI, confidence interval 
 
Table 2 Results of univariable analyses related to signalment and final multivariable model for 
association with death-in hospital. Variables associated with death-in hospital (P<0.20) in 
univariable analyses were included in initial multivariable regression analysis. Variables 
significantly associated with death-in hospital (P<0.05) were retained in the final multivariable 
regression analysis. 
 
Signalment Variable Univariable 
OR (95% 
CI) 
Univariable 
P 
Multivariable 
OR (95% CI) 
Multivariable 
 P b 
Sex Female:  
93/612 
(15.2%) 
Male: 
86/582 
(14.8%) 
1.02 (0.73-
1.41) 
0.925   
Neutered 
status 
Neutered: 
162/1042 
(15.6%) 
Entire: 
17/152 
(11.2%) 
1.69 (0.95-
3.01) 
0.072a   
Age 
(years) 
Continuous (range 2-
17) 
1.14 (1.07-
1.22) 
<0.001a 1.17 (1.08-
1.26) 
<0.001 
OR, odds ratio; CI, confidence interval 
a P<0.20 in univariable analysis and included in initial multivariable regression analysis 
b P<0.05 in final multivariable regression analysis 
 
Table 3 Results of univariable analyses related to the 10 most frequent breeds and final 
multivariable model for association with death-in hospital. Variables associated with death-in 
hospital (P<0.20) in univariable analyses were included in initial multivariable regression analysis. 
Variables significantly associated with death-in hospital (P<0.05) were retained in the final 
multivariable regression analysis. 
 
Breed (10 
most 
frequent) 
Yes No Univariable 
OR (95% 
CI) 
Univariable 
P-value 
Multivariable 
OR (95% CI) 
Multivariable 
P 
Mixed breed 25/188 
(13.2%) 
154/1006 
(15.3%) 
0.93 (0.58-
1.50) 
0.768   
Shetland 
sheepdog 
19/126 
(15.1%) 
160/1068 
(15.0%) 
1.10 (0.65-
1.88) 
0.730   
Cocker 
spaniel 
11/74 
(14.9%) 
168/1120 
(15.0%) 
0.92 (0.47-
1.83) 
0.821   
Miniature 
schnauzer 
3/63 
(4.8%) 
176/1131 
(15.6%) 
0.27 (0.08-
0.88) 
0.030a   
Bichon frise 6/58 
(10.3%) 
173/1136 
(15.2%) 
0.59 (0.24-
1.42) 
0.240   
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Beagle 7/54 
(13.0%) 
172/1140 
(15.1%) 
0.84 (0.37-
1.93) 
0.687   
Pomeranian 11/48 
(22.9%) 
168/1146 
(14.7%) 
1.67 (0.82-
3.42) 
0.159a 2.46 (1.10-
5.50)b 
0.029 
Border 
terrier 
8/41 
(19.5%) 
171/1153 
(14.8%) 
1.58 (0.65-
3.87) 
0.315   
Chihuahua 3/36 
(8.3%) 
176/1158 
(15.2%) 
0.51 (0.15-
1.69) 
0.269   
Shih tzu 4/34 
(11.8%) 
175/1160 
(15.1%) 
0.72 (0.24-
2.11) 
0.547   
OR, odds ratio; CI, confidence interval 
a P<0.20 in univariable analysis and included in initial multivariable regression analysis 
b Confounding present: Pomeranian breed confounded by variables of jaundice and vomiting. 
Table 4. Results of univariable analyses related to clinical signs and final multivariable model for 
association with death-in hospital. Variables associated with death-in hospital (P<0.20) in 
univariable analyses were included in initial multivariable regression analysis. Variables 
significantly associated with death-in hospital (P<0.05) were retained in the final multivariable 
regression analysis. 
 
Clinical sign Present Abse
nt 
Univariabl
e 
OR (95% 
CI) 
Univar
iable 
P 
Multivariable 
OR (95% CI) 
Multivar
iable 
P b 
Time clinical 
(days) 
Continuous (range 
0-135) 
0.99 (0.99-
1.00) 
0.450   
Any sign 168/982 
(17.1%) 
10/2
11 
(4.7
%) 
4.20 (2.14-
8.23) 
<0.001
a 
Collinear with 
jaundice/vomiting 
 
Jaundice  29/96 
(30.2%) 
139/
882 
(15.8
%) 
2.33 (1.40-
3.89) 
0.001a 2.12 (1.19-3.77) 0.011 
Hyporexia 23/110 
(20.9%) 
145/
868 
(16.7
%) 
1.23 (0.72-
2.17) 
0.451   
Painful 
abdomen 
25/164 
(15.2%) 
143/
814 
(17.6
%) 
0.85 (0.52-
1.40) 
0.531   
Anorexia 78/454 
(17.2%) 
90/5
24 
(17.2
%) 
1.05 (0.73-
1.50) 
0.785   
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Diarrhea 36/180 
(20.0%) 
132/
798 
(16.5
%) 
1.19 (0.78-
1.82) 
0.419   
Vomiting 121/786 
(15.4%) 
47/1
92 
(24.5
%) 
0.52 (0.34-
0.78) 
0.001a 0.48 (0.31-0.75) 0.001 
Lethargy 71/458 
(15.5%) 
97/5
20 
(18.7
%) 
0.80 (0.56-
1.14) 
0.214   
OR, odds ratio; CI, confidence interval 
a P<0.20 in univariable analysis and included in initial multivariable regression analysis 
b P<0.05 in final multivariable regression analysis 
 
Table 5. Results of univariable analyses related to clinicopathological findings/comorbidity and 
final multivariable model for association with death-in hospital. Variables associated with death-
in hospital (P<0.20) in univariable analyses were included in initial multivariable regression 
analysis. Variables significantly associated with death-in hospital (P<0.05) were retained in the 
final multivariable regression analysis. 
 
Clinicopathological 
findings / comorbidity 
Pres
ent 
Absent Univariab
le 
OR (95% 
CI) 
Univari
able 
P 
Multivari
able 
OR (95% 
CI) 
Multivaria
ble 
P b 
Fold change in total 
serum/plasma bilirubin 
Continuous 
(range 0-135) 
1.03 
(1.02-
1.04) 
<0.001a 1.03 
(1.01-
1.04) 
<0.001 
Hyperlipidemia 77/5
85 
(13.
2%) 
12/59 
(20.3%) 
0.62 
(0.29-
1.31) 
0.210   
Hypertriglyceridemia 19/1
12 
(17.
0%) 
15/120 
(12.5%) 
1.61 
(0.69-
3.79) 
0.273   
Hypercholesterolemia 74/5
59 
(13.
2%) 
67/449 
(14.9%) 
0.93 
(0.64-
1.35) 
0.695   
Diabetes mellitus 13/6
9 
(18.
8%) 
166/1125 
(14.8%) 
1.39 
(0.73-
2.66) 
0.315   
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Hypothyroidism 12/7
3 
(16.
4%) 
167/1121 
(14.9%) 
1.20 
(0.62-
2.30) 
0.595   
Hyperadrenocorticism 27/1
20  
(22.
5%) 
152/1074 
(14.2%) 
1.68 
(1.04-
2.70) 
0.035a 1.94 
(1.08-
3.47) 
0.026 
OR, odds ratio; CI, confidence interval 
a P<0.20 in univariable analysis and included in initial multivariable regression analysis 
b P<0.05 in final multivariable regression analysis 
 
